Wall Street analyst estimates for Eledon Pharmaceuticals, Inc. (ELDN): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating innovative treatments for individuals battling autoimmune disorders, amyotrophic lateral sclerosis (ALS), and those undergoing organ or cell transplantation. Their flagship therapeutic candidate, AT-1501, is a humanized monoclonal antibody engineered to specifically target CD40 Ligand, a crucial protein found on the surface of immune system T cells.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-13 | $-0.20 | ||
| 2026-08-13 | $-0.27 | $-0.16 | -70.9% |
| 2026-05-13 | $-0.33 | $-0.22 | -50.0% |
| 2026-03-19 | $-0.10 | $-0.20 | +50.0% |
| 2025-11-14 | $-0.21 | $-0.22 | +4.5% |
| 2025-08-14 | $-0.13 | $-0.23 | +43.5% |
| 2025-05-14 | $-0.08 | $-0.28 | +71.4% |
| 2025-03-20 | $-0.64 | $-0.32 | -100.0% |
Valuation Ratios
| Price / Book | 4.21 |
| EV / EBITDA | -2.80 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | $35000 | $22000 | $11000 | $182000 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -$35000 | -$22000 | -$11000 | -$182000 | 0 | 0 | 0 | 0 | 0 | 0 |
| Research & Development | $25.0M | $2.0M | $6.8M | $8.1M | $6.1M | $23.7M | $27.1M | $30.3M | $52.0M | $66.3M |
| Selling, General & Admin | $13.1M | $11.1M | $7.2M | $5.9M | $10.1M | $13.1M | $12.7M | $12.7M | $18.6M | $17.0M |
| Operating Expenses | $38.1M | $13.1M | $14.1M | $14.0M | $18.5M | $36.9M | $88.4M | $43.0M | $70.6M | $83.3M |
| Operating Income | -$38.1M | -$13.1M | -$14.1M | -$14.2M | -$18.5M | -$36.9M | -$88.4M | -$43.0M | -$70.6M | -$83.3M |
| EBITDA | -$6.9M | -$13.1M | -$14.0M | -$15.8M | -$16.0M | -$36.7M | -$39.4M | -$116.2M | -$35.4M | -$45.3M |
| Interest Expense | 0 | 0 | 0 | 0 | $9.7M | 0 | 0 | 0 | 0 | 0 |
| Pre-tax Income | -$38.0M | -$13.1M | -$14.1M | -$16.0M | -$23.2M | -$36.9M | -$88.0M | -$116.5M | -$35.8M | -$45.6M |
| Income Tax | $136000 | 0 | -$5000 | 0 | -$404000 | -$2.4M | 0 | 0 | $431000 | $35000 |
| Net Income | -$38.0M | -$13.1M | -$14.1M | -$16.0M | -$22.8M | -$34.5M | -$88.0M | -$116.5M | -$36.2M | -$45.6M |
| EPS | $-398.52 | $-41.40 | $-28.11 | $-24.42 | $-17.16 | $-2.33 | $-6.16 | $-4.73 | $-0.75 | $-0.56 |
| EPS (Diluted) | $-398.52 | $-41.40 | $-28.11 | $-24.42 | $-17.16 | $-2.33 | $-6.16 | $-4.73 | $-0.75 | $-0.56 |
| Shares Outstanding (Diluted) | $4.2M | $4.7M | $9.0M | $11.8M | $15.2M | $14.8M | $14.3M | $24.6M | $48.5M | $81.8M |
Price
| Price | $2.67 |
| Market Cap | $206M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ABEO · ACHV · ALLO · AVIR · EDIT · HUMA · PBYI
Explore sector: Healthcare · Biotechnology
More sections of ELDN: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks